Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Ibrutinib alone and in combination with rituximab for older patients with chronic lymphocytic leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.12.18
Views: 714

Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Centre, Columbus, USA

Dr Jennifer Woyach speaks to ecancer at ASH 2018 about treatments for older adults with chronic lymphocytic leukaemia (CLL).

She explains that the Phase III trial that aimed to discover whether targeted therapy with the bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is better than current standard of care, and whether the addition of rituximab improved its efficacy over ibrutinib alone.

She also comments on the practice changing potential of the trial for older patients.

Dr Woyach concludes that there has been a significantly improved progression free survival for patients treated on either of the ibrutinib arms.

Watch Dr Woyach's press conference here.

Read the article about this work here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation